Skip to main content
SpringerLink
Log in

Basic Pharmacokinetic Principles

  • Chapter
  • First Online:
Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill

Abstract

The goal of antibiotic drug development is to define optimized dosing regimens that produce maximal therapeutic efficacy with minimal toxic effects. Pharmacokinetics describes the relationship between dose administered and time course of drug concentration and is characterized by systemic input and disposition kinetic processes. An understanding of drug pharmacokinetics is therefore necessary to optimize drug therapy and provide dose recommendation in populations of interest. Here, we review the basic principles defining drug pharmacokinetics, followed by an overview of the methods associated with data analysis and parameter estimation. We then briefly explore the pharmacodynamic indices relevant to antibiotic dosing and discuss how physiological alterations in critically ill patients may influence drug pharmacokinetics. Finally, we provide some examples of pharmacokinetic dosing considerations for specific classes of antibiotic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Begg EJ (2008) Instant clinical pharmacology, 2nd edn. Blackwell, Christchurch

    Google Scholar 

  2. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Williams & Wilkins, Philadelphia

    Google Scholar 

  3. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB (2009) The time course of drug effects. Pharm Stat 8(3):176–185. doi:10.1002/pst.393

    Article  PubMed  Google Scholar 

  4. Holford N (1992) Clinical pharmacokinetics and pharmacodynamics: the quantitative basis for therapeutics. In: Melmon K, Morrelli H, Nierenberg D, Hoffman B (eds) Melmon and morrelli’s clinical pharmacology: basic principles in therapeutics, 3rd edn. McGraw-Hill, New York, p 1141

    Google Scholar 

  5. Welling PG (1995) Differences between pharmacokinetics and toxicokinetics. Toxicol Pathol 23(2):143–147

    Article  CAS  PubMed  Google Scholar 

  6. Nauta EH, Mattie H (1976) Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. Clin Pharmacol Ther 20(1):98–108

    Article  CAS  PubMed  Google Scholar 

  7. Paintaud G, Alvan G, Dahl ML, Grahnen A, Sjovall J, Svensson JO (1992) Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol 43(3):283–288

    Article  CAS  PubMed  Google Scholar 

  8. Patel K, Kirkpatrick CM (2011) Pharmacokinetic concepts revisited—basic and applied. Curr Pharm Biotechnol 12(12):1983–1990

    Article  CAS  PubMed  Google Scholar 

  9. Bauer LA, Blouin RA (1983) Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 24(5):639–642

    Article  CAS  PubMed  Google Scholar 

  10. Bauer LA, Blouin RA (1982) Gentamicin pharmacokinetics: effect of aging in patients with normal renal function. J Am Geriatr Soc 30(5):309–311

    Article  CAS  PubMed  Google Scholar 

  11. Ulldemolins M, Rello J (2011) The relevance of drug volume of distribution in antibiotic dosing. Curr Pharm Biotechnol 12(12):1996–2001

    Article  CAS  PubMed  Google Scholar 

  12. Petrosillo N, Giannella M, Lewis R, Viale P (2013) Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti-Infect Ther 11(2):159–177

    Article  CAS  PubMed  Google Scholar 

  13. Bulitta JB, Holford NHG (2014) Non-compartmental analysis. In: Statistics reference online. Wiley. doi:10.1002/9781118445112.stat06889

  14. DiStefano JJ III (1982) Noncompartmental vs. compartmental analysis: some bases for choice. Am J Phys 243(1):R1–R6

    Google Scholar 

  15. Sheiner LB (1984) The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15(1–2):153–171. doi:10.3109/03602538409015063

    Article  CAS  PubMed  Google Scholar 

  16. Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38. doi:10.1038/psp.2013.14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1:e6. doi:10.1038/psp.2012.4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hennig S, Norris R, Kirkpatrick CM (2008) Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis—a population pharmacokinetic study. Br J Clin Pharmacol 65(4):502–510. doi:10.1111/j.1365-2125.2007.03045.x

    Article  CAS  PubMed  Google Scholar 

  19. Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ, Darlow BA (2001) An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother 48(6):887–893

    Article  CAS  PubMed  Google Scholar 

  20. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37(3):840–851.; Quiz 859. doi:10.1097/CCM.0b013e3181961bff

    Article  CAS  PubMed  Google Scholar 

  21. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481–504

    Article  CAS  PubMed  Google Scholar 

  22. Holford N, Heo YA, Anderson B (2013) A pharmacokinetic standard for babies and adults. J Pharm Sci 102(9):2941–2952. doi:10.1002/jps.23574

    Article  CAS  PubMed  Google Scholar 

  23. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM (2006) Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 58(5):987–993. doi:10.1093/jac/dkl349

    Article  CAS  PubMed  Google Scholar 

  24. Roos JF, Lipman J, Kirkpatrick CM (2007) Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 33(5):781–788. doi:10.1007/s00134-007-0573-7

    Article  CAS  PubMed  Google Scholar 

  25. Roberts JA, Field J, Visser A, Whitbread R, Tallot M, Lipman J, Kirkpatrick CM (2010) Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 54(9):3635–3640. doi:10.1128/aac.00222-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM (2011) Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 55(12):5868–5873. doi:10.1128/aac.00424-11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Matthews I, Kirkpatrick C, Holford N (2004) Quantitative justification for target concentration intervention—parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 58(1):8–19. doi:10.1111/j.1365-2125.2004.02114.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 17(3):479–501

    Article  Google Scholar 

  29. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276(5309):122–126

    Article  CAS  PubMed  Google Scholar 

  30. West GB, Brown JH, Enquist BJ (1999) The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284(5420):1677–1679

    Article  CAS  PubMed  Google Scholar 

  31. Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM (2004) A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 43(15):1167–1178. doi:10.2165/00003088-200443150-00007

    Article  PubMed  Google Scholar 

  32. Han PY, Duffull SB, Kirkpatrick CM, Green B (2007) Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 82(5):505–508. doi:10.1038/sj.clpt.6100381

    Article  CAS  PubMed  Google Scholar 

  33. van der Poll T (2001) Immunotherapy of sepsis. Lancet Infect Dis 1(3):165–174. doi:10.1016/s1473-3099(01)00093-7

    Article  PubMed  Google Scholar 

  34. Gosling P, Sanghera K, Dickson G (1994) Generalized vascular permeability and pulmonary function in patients following serious trauma. J Trauma 36(4):477–481

    Article  CAS  PubMed  Google Scholar 

  35. Arredondo G, Martinez-Jorda R, Calvo R, Aguirre C, Suarez E (1994) Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 32(7):361–364

    CAS  PubMed  Google Scholar 

  36. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T (2001) The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 47(4):421–429

    Article  CAS  PubMed  Google Scholar 

  37. Vogelman B, Craig WA (1986) Kinetics of antimicrobial activity. J Pediatr 108(5 Pt 2):835–840

    Article  CAS  PubMed  Google Scholar 

  38. Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ (1988) Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 16(4):418–422

    CAS  PubMed  Google Scholar 

  39. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA (2002) Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28(7):936–942. doi:10.1007/s00134-002-1313-7

    Article  CAS  PubMed  Google Scholar 

  40. Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A (1990) Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 16(5):303–306

    Article  CAS  PubMed  Google Scholar 

  41. McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31(4):345–351. doi:10.1016/j.ijantimicag.2007.12.009

    Article  CAS  PubMed  Google Scholar 

  42. Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30(5):976–979. doi:10.1007/s00134-004-2222-8

    Article  PubMed  Google Scholar 

  43. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ (1999) Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 43(2):309–311

    Article  CAS  PubMed  Google Scholar 

  44. Cooper BE, Nester TJ, Armstrong DK, Dasta JF (1986) High serum concentrations of mezlocillin in a critically ill patient with renal and hepatic dysfunction. Clin Pharm 5(9):764–766

    CAS  PubMed  Google Scholar 

  45. Green L, Dick JD, Goldberger SP, Angelopulos CM (1985) Prolonged elimination of piperacillin in a patient with renal and liver failure. Drug Intell Clin Pharm 19(6):427–429

    Article  CAS  PubMed  Google Scholar 

  46. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR (2005) Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 44(5):539–549

    Article  CAS  PubMed  Google Scholar 

  47. Li C, Kuti JL, Nightingale CH, Nicolau DP (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46(10):1171–1178. doi:10.1177/0091270006291035

    Article  CAS  PubMed  Google Scholar 

  48. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE (2005) Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49(9):3624–3630. doi:10.1128/aac.49.9.3624-3630.2005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Nation RL, Li J (2007) Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 28(6):604–614. doi:10.1055/s-2007-996407

    Article  PubMed  Google Scholar 

  50. Smith RP, Baltch AL, Franke MA, Michelsen PB, Bopp LH (2000) Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 45(4):483–488

    Article  CAS  PubMed  Google Scholar 

  51. Kiser TH, Hoody DW, Obritsch MD, Wegzyn CO, Bauling PC, Fish DN (2006) Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother 50(6):1937–1945. doi:10.1128/aac.01466-05

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M (2003) Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 42(6):589–598

    Article  CAS  PubMed  Google Scholar 

  53. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37(5):1073–1081

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M (1998) Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279(2):125–129

    Article  CAS  PubMed  Google Scholar 

  55. Llopis-Salvia P, Jimenez-Torres NV (2006) Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 31(5):447–454. doi:10.1111/j.1365-2710.2006.00762.x

    Article  CAS  PubMed  Google Scholar 

  56. Macias WL, Mueller BA, Scarim SK (1991) Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 50(6):688–694

    Article  CAS  PubMed  Google Scholar 

  57. Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J, Roberts JA (2013) Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents 41(6):564–568. doi:10.1016/j.ijantimicag.2013.01.018

    Article  CAS  PubMed  Google Scholar 

  58. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166(19):2138–2144. doi:10.1001/archinte.166.19.2138

    Article  PubMed  Google Scholar 

  59. MacGowan AP (2003) Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51(Suppl 2):ii17–ii25. doi:10.1093/jac/dkg248

    CAS  PubMed  Google Scholar 

  60. Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O’Grady M, Hopkins NK, Jungbluth GL (2003) Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 47(9):2775–2780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Monash University, Melbourne, VIC, Australia

    Kashyap Patel & Carl M. Kirkpatrick

  2. d3 Medicine, A Certara Company, Melbourne, VIC, Australia

    Kashyap Patel

Authors
  1. Kashyap Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl M. Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kashyap Patel .

Editor information

Editors and Affiliations

  1. Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

    Andrew A. Udy

  2. Burns, Trauma and Critical Care Research Centre, The University of Queensland, Herston, Queensland, Australia

    Jason A. Roberts

  3. Burns, Trauma and Critical Care Research Centre, The University of Queensland, Herston, Queensland, Australia

    Jeffrey Lipman

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Patel, K., Kirkpatrick, C.M. (2018). Basic Pharmacokinetic Principles. In: Udy, A., Roberts, J., Lipman, J. (eds) Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. Adis, Singapore. https://doi.org/10.1007/978-981-10-5336-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-5336-8_1

  • Published:

  • Publisher Name: Adis, Singapore

  • Print ISBN: 978-981-10-5335-1

  • Online ISBN: 978-981-10-5336-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation